Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
Phase I: The goal of this clinical research study is to find the highest dose of estramustine
phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel)
that can be given safely to participants with prostate cancer who have failed to further
benefit from hormone treatment.
Phase II: The goal of this clinical research study is to find out if the combination of the
drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has
not responded to hormone treatment. A second goal is to find out if the side effects of these
drugs can be reversed. The safety of these drugs will also be studied.